Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and the ...

ACE inhibitors are well-established for limiting morbidity and mortality after MI, particularly in patients with LV dysfunction, heart failure, or both. To test the hypothesis that an ...

DALLAS, Aug. 17 – Iron supplements may be a simple remedy for the “common cough” associated with a widely used cardiovascular drug, according to a study in this month’s Hypertension: Journal of the ...

Since the introduction of ARBs, the question that has pervaded each clinician’s mind is whether or not these drugs serve an advantage in conditions long addressed by ACE inhibitors. Matchar et al ...

OBJECTIVES: Many patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) experience a delay in treatment or fail to initiate treatment with guideline-recommended angiotensin-converting ...

Angiotensin converting enzyme (ACE) inhibitors, a type of blood pressure medication, are usually well tolerated, but one of their rare side effects is angioedema. Angiotensin converting enzyme (ACE) ...

For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI ...

An ACE inhibitor can prevent or reduce heart enlargement. * THE QUESTION Does a drug that fights high blood pressure also prevent or limit thickening of the heart, and would it reduce illness or death ...